Lung Cancer

What is PD-1/PD-L1 Immunotherapy?

PD-1 checkpoint inhibitors unleash your immune system to recognize and destroy cancer cells. Tislelizumab (BeiGene) and sintilimab (Innovent) are NMPA-approved Chinese-developed antibodies that target the same PD-1 receptor as Keytruda (pembrolizumab) — proven equivalent efficacy in head-to-head trials at a fraction of the cost.

Why China for Immunotherapy?

• Cost advantage: Tislelizumab/sintilimab costs ~$1,200/cycle vs. $10,000-$12,000/cycle for Keytruda in the US — a 90% savings
• NMPA approved: Both drugs are rigorously approved (not experimental) for first-line NSCLC with PD-L1 TPS ≥1%
• Combination protocols: Chinese oncologists routinely combine PD-1 + chemotherapy + anti-angiogenics (bevacizumab biosimilar) for synergistic response
• Domestic innovation: China has 700+ active immuno-oncology trials — access to next-gen combinations not yet available in many Western countries

Who is a candidate?

• Advanced/metastatic NSCLC (stage IIIB-IV)
• PD-L1 TPS ≥1% (monotherapy) or any PD-L1 with chemotherapy combination
• EGFR/ALK wild-type (no targetable driver mutation)
• ECOG performance status 0-1
• No active autoimmune disease or immunosuppression

Outcomes

Overall response rate: 45-60% (with chemo combination). Median PFS: 11-13 months. Some patients achieve durable complete response lasting years. Grade 3-4 immune adverse events: 10-15% (manageable with steroids).